Loading
Everything OnCo dates to 1978: 13 entries, 5 companies founded, 3 journals founded, 2 approvals and 2 landmarks. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.
13 dated entries in OnCo fall in 1978: 5 companies founded, 3 journals founded, 2 approvals, 2 landmarks and 1 paper.
Of those, 13 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.
Everything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.
The approvals rows on treatment records: region, year and indication.
Hyperprolactinaemia-associated dysfunction including prolactin-secreting adenomas; acromegaly; Parkinson's disease
Testicular and ovarian cancer; bladder cancer 1993
The publication year on key paper records.
Traverso LW, Longmire WP. Surgery, Gynecology and Obstetrics.
The history entries editors wrote on cancer records: the dated turning points of each disease.
Pancreatic ductal adenocarcinoma. Traverso and Longmire, two patients; their 1980 follow-up of 18 found every patient had exocrine insufficiency and needed enzyme replacement.
Glioma & glioblastoma. Whole-brain then involved-field radiation becomes standard.
The founded year on company records.
Bengaluru
Cambridge, MA
Newcastle, NSW
Cologne
London
The founded year on journal records.
Springer
Wolters Kluwer (Lippincott Williams & Wilkins)
Routledge (Taylor & Francis)